CytoSolv Inc. is a biotechology company organized around developing cell-based therapeutics, wound-healing technology derived from porcine choroid plexus. In addition to its cell-derived protein product for improving the healing of problematic wounds of the skin and abdominal fascia, Cytosolv is also developing encapsulation systems and methodologies for systemic delivery of proteins secreted by living cells. These systems are tailored to provide long-term therapeutic delivery to treat chronic diseases with stem cells, engineered cell lines, or primary tissue. In 2015, it was announced that the firrm had been acquired by Cambridge, MA based Semma Therapeutics, a VC backed firm founded in 2015 to develop transformative therapies for Type 1 diabetes patient. CytoSolv continues operations in Rohode Island.
